Hyperinsulinemia ' Pipeline Review, H2 2012
Summary
Global Markets Direct's, 'Hyperinsulinemia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperinsulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperinsulinemia. Hyperinsulinemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Hyperinsulinemia.- A review of the Hyperinsulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Hyperinsulinemia pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hyperinsulinemia.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Hyperinsulinemia pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013
Hyperinsulinemia ' Pipeline Review, H2 2012
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Hyperinsulinemia ' Pipeline Review, H2 2012
Published on December 2012
Report Summary
Hyperinsulinemia ' Pipeline Review, H2 2012
Summary
Global Markets Direct's, 'Hyperinsulinemia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline.
This report provides information on the therapeutic development for Hyperinsulinemia, complete with latest updates, and special
features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for
Hyperinsulinemia. Hyperinsulinemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets
Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.
Scope
- A snapshot of the global therapeutic scenario for Hyperinsulinemia.
- A review of the Hyperinsulinemia products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hyperinsulinemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hyperinsulinemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hyperinsulinemia pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Hyperinsulinemia ' Pipeline Review, H2 2012 (From Slideshare) Page 1/6
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hyperinsulinemia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hyperinsulinemia 7
Hyperinsulinemia Therapeutics under Development by Companies 9
Hyperinsulinemia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Hyperinsulinemia Therapeutics ' Products under Development by Companies 15
Hyperinsulinemia Therapeutics ' Products under Investigation by Universities/Institutes 16
Companies Involved in Hyperinsulinemia Therapeutics Development 17
Biodel Inc. 17
Amunix, Inc. 18
Hyperinsulinemia ' Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
glucagon - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
diazoxide - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
exendin-(9-39) - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
diazoxide - Drug Profile 28
Product Description 28
Hyperinsulinemia ' Pipeline Review, H2 2012 (From Slideshare) Page 2/6
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Mechanism of Action 28
R&D Progress 28
glucagon - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Metformin + Abiraterone - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Hyperinsulinemia Therapeutics ' Drug Profile Updates 31
Hyperinsulinemia Therapeutics - Dormant Products 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34
List of Tables
Number of Products Under Development for Hyperinsulinemia, H2 2012 7
Products under Development for Hyperinsulinemia ' Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Biodel Inc., H2 2012 17
Amunix, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Hyperinsulinemia Therapeutics ' Drug Profile Updates 31
Hyperinsulinemia Therapeutics ' Dormant Products 32
List of Figures
Hyperinsulinemia ' Pipeline Review, H2 2012 (From Slideshare) Page 3/6
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Number of Products under Development for Hyperinsulinemia, H2 2012 7
Products under Development for Hyperinsulinemia ' Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 19
Assessment by Combination Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24
Hyperinsulinemia ' Pipeline Review, H2 2012 (From Slideshare) Page 4/6
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Hyperinsulinemia ' Pipeline Review, H2 2012
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 2 000.00 Quantity: _____
Site License--USD 4 000.00 Quantity: _____
Corporate License--USD 6 000.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Hyperinsulinemia ' Pipeline Review, H2 2012 (From Slideshare) Page 5/6
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Hyperinsulinemia ' Pipeline Review, H2 2012 (From Slideshare) Page 6/6